Senti Biosciences Holdings, Inc. (SNTI): Cash & Equivalents
$16.42M
As of 2025-12-31
$6.46M
As of 2026-06-30
-34.2%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.42M | -66.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $48.28M | +34.4% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $35.93M | -37.7% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $57.62M | +2.8% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $56.03M | n/a | 2023-03-22, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $16.42M | -66.0% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $7.11M | -17.9% |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | $24.75M | +18.3% |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | $2.98M | +75.5% |
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | $5.02M | -55.6% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $17.47M | -66.1% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $94.53M | +680.1% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
Compare SNTI, ENTX, INMB, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗